The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Landscape of Acquired Resistance to Osimertinib in EGFR -Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion
Open accessAbstract
We present a cohort of 41 patients with osimertinib resistance biopsies, including 2 with an acquired CCDC6–RET fusion. Although RET fusions have been identified in resistant EGFR-mutant non–small cell lung cancer (NSCLC), their role in acquired resistance to EGFR inhibitors is not well described. To assess the biological implications of RET fusions in an EGFR-mutant cancer, we expressed CCDC6–RET in PC9 (EGFR del19) and MGH134 (EGFR L858R/T790M) cells and found that CCDC6–RET was sufficient to confer resistance to EGFR tyrosine kinase inhibitors (TKI). The selective RET inhibitors BLU-667 and cabozantinib resensitized CCDC6–RET-expressing cells to EGFR inhibition. Finally, we treated 2 patients with EGFR-mutant NSCLC and RET-mediated resistance with osimertinib and BLU-667. The combination was well tolerated and led to rapid radiographic response in both patients. This study provides proof of concept that RET fusions can mediate acquired resistance to EGFR TKIs and that combined EGFR and RET inhibition with osimertinib/BLU-667 may be a well-tolerated and effective treatment strategy for such patients. Significance: The role of RET fusions in resistant EGFR-mutant cancers is unknown. We report that RET fusions mediate resistance to EGFR inhibitors and demonstrate that this bypass track can be effectively targeted with a selective RET inhibitor (BLU-667) in the clinic. This article is highlighted in the In This Issue feature, p. 1494
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
Self-citationMET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612674 · Cited by 3,379
Yu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., Kris, M. G., Miller, V. A., Ladanyi, M., & Riely, G. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2246 · Cited by 2,454
Cross, D. A. E., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R. V., Ward, R. A., Mellor, M. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0337 · Cited by 2,246
Frampton, G. M., Fichtenholtz, A., Otto, G. A., Wang, K., Downing, S. R., He, J., Schnall-Levin, M., White, J., Sanford, E. M., An, P., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2696 · Cited by 2,157 · cited 1×
“All osimertinib-resistant tissue biopsies were analyzed by Clinical Laboratory Improvement Amendments–certified assays performed in the MGH Center for Integrated Diagnostics or Foundation Medicine using methods which have been described previously, including the MGH SNaPshot NGS panel, MGH SFA, FoundationOne NGS panel…”
MethodThress, K. S., Paweletz, C. P., Felip, E., Cho, B. C., Stetson, D., Dougherty, B., Lai, Z., Markovets, A., Vivancos, A., Kuang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3854 · Cited by 1,589
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
Zhou, W., Ercan, D., Chen, L., Yun, C.-H., Li, D., Capelletti, M., Cortot, A. B., Chirieac, L., Iacob, R. E., Padera, R., et al. (2009) · Nature · doi:10.1038/nature08622 · Cited by 1,013
Hata, A. N., Niederst, M. J., Archibald, H. L., Gomez-Caraballo, M., Siddiqui, F. M., Mulvey, H. E., Maruvka, Y. E., Ji, F., Bhang, H.-E. C., Krishnamurthy Radhakrishna, V., et al. (2016) · Nature Medicine · doi:10.1038/nm.4040 · Cited by 985
Self-citationAnchored multiplex PCR for targeted next-generation sequencing
Zheng, Z., Liebers, M., Zhelyazkova, B., Cao, Y., Panditi, D., Lynch, K. D., Chen, J., Robinson, H. E., Shim, H. S., Chmielecki, J., et al. (2014) · Nature Medicine · doi:10.1038/nm.3729 · Cited by 915
Self-citationOvercoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
Jia, Y., Yun, C.-H., Park, E., Ercan, D., Manuia, M., Juarez, J., Xu, C., Rhee, K., Chen, T., Zhang, H., et al. (2016) · Nature · doi:10.1038/nature17960 · Cited by 886
Patient-derived models of acquired resistance can identify effective drug combinations for cancer
Crystal, A. S., Shaw, A. T., Sequist, L. V., Friboulet, L., Niederst, M. J., Lockerman, E. L., Frias, R. L., Gainor, J. F., Amzallag, A., Greninger, P., et al. (2014) · Science · doi:10.1126/science.1254721 · Cited by 708
Self-citationOxnard, G. R., Hu, Y., Mileham, K. F., Husain, H., Costa, D. B., Tracy, P., Feeney, N., Sholl, L. M., Dahlberg, S. E., Redig, A. J., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.2969 · Cited by 686 · cited 1×
“In addition to the fusion cases discussed, we observed C797S in 27% of patients, consistent with other experiences (4).”
ResultNiederst, M. J., Hu, H., Mulvey, H. E., Lockerman, E. L., Garcia, A. R., Piotrowska, Z., Sequist, L. V., & Engelman, J. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0560 · Cited by 583
Self-citationUchibori, K., Inase, N., Araki, M., Kamada, M., Sato, S., Okuno, Y., Fujita, N., & Katayama, R. (2017) · Nature Communications · doi:10.1038/ncomms14768 · Cited by 409
Precision Targeted Therapy with BLU-667 for RET-Driven Cancers
Subbiah, V., Gainor, J. F., Rahal, R., Brubaker, J. D., Kim, J. L., Maynard, M., Hu, W., Cao, Q., Sheets, M. P., Wilson, D., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0338 · Cited by 396
Self-citationZill, O. A., Banks, K. C., Fairclough, S. R., Mortimer, S. A., Vowles, J. V., Mokhtari, R., Gandara, D. R., Mack, P. C., Odegaard, J. I., Nagy, R. J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3837 · Cited by 391 · cited 1×
“All plasma samples were analyzed by the Guardant360 NGS platform (Guardant Health) as described previously (28).”
MethodSelf-citationScagliotti, G., von Pawel, J., Novello, S., Ramlau, R., Favaretto, A., Barlesi, F., Akerley, W., Orlov, S., Santoro, A., Spigel, D., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.7317 · Cited by 265
Self-citationSchrock, A. B., Zhu, V. W., Hsieh, W.-S., Madison, R. W., Creelan, B., Silberberg, J., Costin, D., Bharne, A., Bonta, I. R., Bosemani, T., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.05.027 · Cited by 150
Self-citationNeal, J. W., Dahlberg, S. E., Wakelee, H. A., Aisner, S. C., Bowden, M., Huang, Y., Carbone, D. P., Gerstner, G. J., Lerner, R. E., Rubin, J. L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30561-7 · Cited by 142
Offin, M. D., Somwar, R., Rekhtman, N., Benayed, R., Chang, J. C., Plodkowski, A. J., Lui, A. J. W., Eng, J., Rosenblum, M. K., Li, B. T., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00126 · Cited by 128
Klempner, S. J., Bazhenova, L. A., Braiteh, F. S., Nikolinakos, P. G., Gowen, K. A., Cervantes, C. M., Chmielecki, J., Greenbowe, J. R., Ross, J. S., Stephens, P. J., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.06.021 · Cited by 91
Self-citationRich, T. A., Reckamp, K. L., Chae, Y. K., Doebele, R. C., Iams, W. T., Oh, M. S., Raymond, V. M., Lanman, R. B., Riess, J. W., Stinchcombe, T. E., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4049 · Cited by 85
Self-citationZhang, Q., Zhang, X., Yang, J., Yang, Z., Bai, Y., Su, J., Wang, Z., Zhang, Z., Shao, Y. W., Zhou, Q. H., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.05.024 · Cited by 82
BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma
Kulkarni, A., Al-hraishawi, H., Simhadri, S. R., Hirshfield, K. M., Chen, S., Pine, S. R., Jeyamohan, C., Sokol, L. O., Ali, S. M., Teo, M. L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0758 · Cited by 71
Janne, P. A., Shaw, A. T., Camidge, D. R., Giaccone, G., Shreeve, S. M., Tang, Y., Goldberg, Z., Martini, J., Xu, H., James, L. P., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.01.022 · Cited by 58
Self-citationMET amplification (amp) as a resistance mechanism to osimertinib.
Piotrowska, Z., Thress, K. S., Mooradian, M. J., Heist, R. S., Azzoli, C. G., Temel, J. S., Rizzo, C., Nagy, R. J., Lanman, R. B., Gettinger, S. N., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.9020 · Cited by 57
Self-citationWakelee, H. A., Gettinger, S. N., Engelman, J. A., Janne, P. A., West, H., Subramaniam, D. S., Leach, J., Wax, M., Yaron, Y., Miles, D., et al. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3283-z · Cited by 39
Ahn, M., Han, J., Sequist, L. V. D., Cho, B. C., Lee, J.-S., Kim, S., Su, W., Tsai, C.-M., Yang, J. C., Yu, H. A., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.09.377 · Cited by 39
Self-citation
Cited by
Thai, A. A., Solomon, B. J., Sequist, L. V., Gainor, J. F., & Heist, R. S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00312-3 · Cited by 2,576
Self-citationResistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
Leonetti, A., Sharma, S., Minari, R., Perego, P., Giovannetti, E., & Tiseo, M. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0573-8 · Cited by 1,409
Acquired Resistance to Immune Checkpoint Inhibitors
Schoenfeld, A. J., & Hellmann, M. D. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.017 · Cited by 955
Lim, Z.-F., & Ma, P. C. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0818-2 · Cited by 630
Overcoming therapy resistance in EGFR-mutant lung cancer
Passaro, A., Jänne, P. A., Mok, T., & Peters, S. (2021) · Nature Cancer · doi:10.1038/s43018-021-00195-8 · Cited by 565
Metadata
- Authors
- Piotrowska, Z., Isozaki, H., Lennerz, J. K., Gainor, J. F., Lennes, I. T., Zhu, V. W., Marcoux, N., Banwait, M. K., Digumarthy, S. R., Su, W., Yoda, S., Riley, A. K., Nangia, V., Lin, J. J., Nagy, R. J., Lanman, R. B., Dias-Santagata, D., Mino-Kenudson, M., Iafrate, A. J., Heist, R. S., Shaw, A. T., Evans, E. K., Clifford, C., Ou, S.-H. I., Wolf, B., Hata, A. N., & Sequist, L. V.
- Venue
- Cancer Discovery
- Published
- 2018-12-01
- Volume
- 8
- Issue
- 12
- Pages
- 1529-1539
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2894066036
- Cited by
- 442
- References
- 29
- FWCI
- 35.85
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.